102
Participants
Start Date
June 6, 2023
Primary Completion Date
June 13, 2025
Study Completion Date
December 12, 2025
CPO301
Administered by intravenous injection
RECRUITING
Fox Chase Cancer Center, Philadelphia
RECRUITING
NEXT Virginia, Fairfax
RECRUITING
Florida Cancer Specialists, Sarasota
RECRUITING
AdventHealth Cancer Institute, Celebration
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Sarah Cannon Research Institute (SCRI) at HealthONE, Denver
RECRUITING
USC Norris Comprehensive Cancer Center, Los Angeles
RECRUITING
UCLA Hematology/Oncology - Santa Monica, Santa Monica
RECRUITING
Hoag Memorial Hospital Presbyterian, Newport Beach
RECRUITING
Dartmouth Hitchcock Medical Center, Lebanon
RECRUITING
Cross Cancer Institute, Edmonton
RECRUITING
Juravinski Cancer Centre, Hamilton
RECRUITING
Princess Margaret Cancer Centre - University Health Network, Toronto
Lead Sponsor
Conjupro Biotherapeutics, Inc.
INDUSTRY